

REMARKS

Foremost, Applicants thanks Examiners Mahatan and Allen for the interview of August 10, 2004. Claims 41-57 are pending. Claims 41-53 are allowed. Claims 54-57 are amended, as discussed below.

It is respectfully submitted that the present amendment presents no new issues or new matter and places this case in condition for allowance. Reconsideration of the application in view of the above amendments and the following remarks is requested.

I. The Rejection of Claims 54-57 under 35 U.S.C. 112, Indefiniteness

Claims 54-57 are rejected under 35 U.S.C. 112, as allegedly indefinite. The Office states that these claims are unclear because it is not clear how many times the steps are repeated, that is, at what point does one stop repeating.

During the interview of August 10, 2004, the Examiner proposed amending the claims to remove the language "recursively" to overcome the rejection. This amendment is acceptable and the claims have been amended accordingly.


For the foregoing reasons, Applicants submit that the claims overcome this rejection under 35 U.S.C. 112. Applicants respectfully request reconsideration and withdrawal of the rejection.

II. Conclusion

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: August 25, 2004


Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097